Loading company…
Revolution Medicines, Inc. is a California cancer medicine developer focused on RAS pathway targets such as RMC-4630.
Based in California, US, Revolution Medicines develops cancer medicines by translating frontier oncology targets, with a pipeline that includes RMC-4630 and mutant-selective RAS(ON) inhibitors. The company raised USD 100 million in a Series C in July 2019 led by Boxer Capital, then USD 238 million in a February 2020 IPO selling 14 million shares at USD 17 per share. It trades on Nasdaq as RVMD, reported USD 42.983 million in revenue for the fiscal year ended December 2020, and Mark A. Goldsmith is CEO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in